Slingshot members are tracking this event:

Alnylam (ALNY) Expects to Initiate Phase 3 Trial in Late 2017 Study Evaluating Givosiran (ALN-AS1) for the Treatment of Acute Hepatic Porphyrias

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 07, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Aln-as1, Phase 1 Study Results, Initiation, Phase 3 Trial, Givosiran